Company Insider: President and CEO of $AVGO Offloads 4,257 Shares

The most recent insider trading activity at $AVGO involves the President and CEO, Hock E Tan, who sold 4,257 shares of the company on December 23, 2025, for an approximate value of $1,443,578. This transaction constituted a sale of about 0.7% of their holdings of this particular class of stock. As a result of this sale, Tan now retains 591,381 shares of $AVGO stock.

Over the past 6 months, insiders at $AVGO have engaged in a total of 187 trades on the open market. Among these transactions, 4 were purchases, while the majority, 183, were sales. Notable figures involved in these sales include Henry Samueli, who has conducted 16 sales amounting to 689,113 shares valued at $252,917,774, and Mark David Brazeal, the Chief Legal & Corporate Affairs Officer, who has made 58 sales totalling 90,012 shares valued at $30,496,501.

Institutional investors have also shown their interest in $AVGO stock, with 2,095 firms adding shares to their portfolios and 1,950 reducing their positions in the last quarter. Significant movements include UBS AM, which added 31,423,170 shares (+78.8%) to their holdings in Q3 2025, and Capital World Investors, who removed 12,713,939 shares (-8.6%) from their portfolio during the same period.

Revenue-wise, $AVGO experienced revenues of $18B in Q4 2025, representing a notable increase of 28.18% from the previous year. This financial data and more can be accessed through Quiver Quantitative’s AVGO stock page.

Congressional members have also participated in trading $AVGO stock, with 18 transactions occurring in the last 6 months. Notable trades include Representative Gilbert Ray Cisneros, Jr. conducting 2 purchases, Representative Cleo Fields engaging in 6 purchases, and Representative Val T. Hoyle selling up to $50,000 on September 23.

Analyst reports reveal that 16 firms have issued buy ratings for $AVGO stock in recent months. Notable among these are Mizuho’s “Outperform” rating on December 12, 2025, and Benchmark’s “Buy” rating on the same date. Similarly, several analysts have offered price targets for $AVGO, with a median target of $450.0 set by 22 analysts in the last 6 months.

It is essential to note that this article is not intended as financial advice and readers are advised to consult Quiver Quantitative’s disclaimers for additional information.